agent morphology history epidemiology transmission reservoir symptoms diagnosis treatment public health
Agent: Fasciola Hepatica (Sheep Liver Fluke) Phylum Platyhelminthe Class Trematoda
Fasciola gigantica very rarely infects humans. Reported cases are mainly form Africa. The life cycle, transmission, morphology, clinical presentation, and treatment of the F. gigantica trematode and its infections are very similar to those of F. hepatica.
The Adult Worm - Averaging 30mm in length and 13 mm in width, Fasciola hepatica is one of the largest flukes in the world. The adult worm has a very characteristic leaf shape with the anterior end being broader than the posterior end and an anterior cone-shaped projection. The fluke possesses a powerful oral sucker at the end the anterior cone and a ventral sucker at the base of the cone which allow it to attach to the lining of the biliary ducts. Each worm possesses ovaries and testes which are highly branched and allow for individual flukes to produce eggs independently.
The Egg - The eggs of Fasciola hepatica are operculated and average 140 μm in length and 75 μm in width.
Follow me to a labeled images of Fasciola hepatica
Eggs of Fasciola hepatica have been found in mummies, showing that human infection was occurring at least as early as Pharaonic times (Farag). Indeed, F. hepatica was the first fluke or trematode to be reported. It was first discovered, however, not in humans, but in sheep where it causes a more obvious burden. A French man, Jehan de Brie, made the earliest references to F. hepatica and accurately recognized the source of infection in his 1379 publication, Le Bon Berger (The Good Shepherd). It is from this early text that F. hepatica required its common name, sheep liver fluke. References to the sheep liver fluke appear in animal husbandry texts throughout the next several centuries until it was given its Latin name by Linnaeus in 1758 and it was not until the late 19th century that F. hepatica's life cycle was elucidated and its role in humans was commonly recognized. Since then, fascioliasis has become one of the most studied hemintichelmintic infections and holds a high-raking position in the minds of public health policy makers.
Fasciola hepatica is found on every continent with nearly 180 million people at risk and an estimated 2.4 million people already infected worldwide. Prevalence is highest in areas where extensive sheep and cattle raising occurs and where dietary practices include the consumption of raw aquatic vegetables. In many locations such as Portugal, the Nile delta, northern Iran, parts of China, and the Andean highlands of Ecuador, Bolivia, and Peru, infections rates are high enough to make fascioliasis a serious public health concern.
The need for temperate, slow-moving or standing water in F. hepatica's life cycle and transmission had previously kept infection limited to populations within well-defined watershed boundaries. Recently however, urbanization, migration, and development practices such as dam building and irrigation have increased the populations at risk and the incidence of human infection has increased significantly over the past 20 years (Chitsulo, Montresor, and Savioli).
There is no vector in Fasciola hepatica transmission.
Transmission occurs through the ingestion of raw, fresh-water vegetation on which the flukes in their metacercariae form are encysted. The plants become exposed to the metacercariae when the body of water that the vegetation is growing in becomes contaminated by eggs in the fecal matter of an infected host. Nearly all cases are a result of watercress consumption, although alfalfa and water lettuce play a large role is some areas. A form of infection known as halzoun that is specific to the Middle East is contracted by eating the raw liver of an infected animal.
Up to 50% of Fasciola hepatica infections are asymptomatic and disease may appear anywhere from a few days to several years after infection (Tolan).
.osinophilia is present with all infections at all stages and can be used as a diagnostic factor in ectopic and early stage infections when eggs are not be present in the stool.
When symptoms do appear, they occur in the following patterns:
Acute Phase The acute phase of infection is rarely seen in humans and occurs only when a large number of metacercariae are ingested at once. Fever, tender hepatomegaly, and abdominal pain are the most frequent symptoms of this stage of infection although vomiting, diarrhea, urticaria (hives), anemia, and may all be present.
The above characteristics of the acute phase are caused by the migration of the F. hepatica larvae throughout the liver parenchyma. The larvae penetrate the liver capsule and begin to produce the above symptoms 4-7 days after ingestion. Migration and thus the acute phase continues for 6-8 weeks until the larvae mature and settle in the bile ducts.
Chronic Phase The symptoms of chronic infection are much more common in human populations and include biliary cholic, abdominal pain, tender hepatomegaly, and jaundice. In children, severe anemia is a common result of infection and is the greatest source of disability from infection in this age group. These symptoms reflect the biliary obstruction and inflammation caused by the presence of the large adult worms and their metabolic waste in the bile ducts. Inflammation of the bile ducts eventually leads to fibrosis and a condition called "pipestem liver", a term describing the white appearance of the biliary ducts after fibrosis. The final outcome of severe infections is portal cirrhosis and even death.
Halzoun The condition commonly known as halzoun is a type of Fasciola hepatica infection in which the worm settles in the pharynx. This occurs when an individual consumes infected raw liver. The young adult worms then attach themselves to the pharyngeal mucosa which causes considerable pain, edema, and bleeding that can interfere with respiration. The adults can live in the biliary ducts, causing symptoms for up to 10 years.
Ectopic Infection Ectopic infections through normal transmission are infrequent but can occur in the peritoneal cavity, intestinal wall, lungs, subcutaneous tissue, and very rarely in other locations.
The definitive and most widely used form of diagnosis is the directly observed presence of Fasciola hepatica eggs either in a stool sample, duodenal aspirate or biliary aspirate.
However, the flukes do not begin to produce eggs until roughly 4 months after infection. Until this time and in the case of ectopic infections where eggs are not present in the stool, serological tests can be used, the FAST-ELISA being the most popular. It has a sensitivity of 95% and can detect specific F. hepatic antibodies as early as 2 weeks after infection (Tolan). False positives are not common although there is some possibility of cross-reactivity with the schistosomiasis antibodies. The FAST-ELISA can also be used to confirm effective cure as antibody levels return to normal in 6-12 months after the cessation of infection.
Ultrasound can be used to visualize the adult flukes in the bile ducts and a CT scan may reveal the burrow tracts made by the worms and dilation of the bile ducts.
Management and Therapy:
Treatment for fascioliasis has a 80-100% success rate.
In many countries, a 5-10 day course of oral bithionol at 30 mg/kg body weight is not only the preferred treatment but the only one available. It is highly effective when administered as above, but the high dose, cost and length of treatment have made it problematic for large-scale control efforts.
Triclabendazole, an antihelmintic agent long used in veterinary medicine, has recently been proven to provide substantial human benefit at much lower doses than bithionol. In 1990, the WHO and pharmaceutical company, Ciba-Geigy, partnered to conduct clinical trials of triclabendazole and found that 1-2 oral doses at 10 mg/kg body weight administered in a single 24 hour period results in virtually no side effects and has a success rate approaching 100%. Following this research, the Ministry of Health of the Arab Republic of Egypt registered triclabendazole for human use and the WHO Expert Committee on the Use of Essential Drugs has recommended that it be added to the WHO's list of essential drugs (Chitsulo, Montresor, and Savioli). Triclabendazole remains unavailable in most countries but its future both in terms of individual treatment and broad-scale public health measures appears very promising.
Along with pharmaceutical therapy, surgery may be necessary in very extreme cases to clear the biliary tract.
Public Health and Prevention Strategies:
The presence of infection in a population is dependent upon and exacerbated by four factors:
Useful Web Links:
Cambridge University Schistosome Research Group http://www.path.cam.ac.uk
Center for Disease Control: Parasitology section http://www.dpd.cdc.gov
Graphic Images of Parasites at the Ohio State University http://www.biosci.ohio-state.edu/parasite/images.html
World Health Organization http://www.who.int
Chitsulo, Montresor, and Savioli. "New opportunities for the control of fascioliasis." Bulletin of the World Health Organization. 16 May 2001 <http://www.who.int/bulletin/editorials/issue4/fascioliasis>.
Farag, Hoda. "Human fascioliasis in some countries of the Middle Eastern Region.." Eastern Mediterranean Region Office of the WHO. 22 May 2001 <http://www.emro.who.int/publications/emlij/0401/24.htm>.
"Fasciola Hepatica." Parasitology.org. 16 May 2001 <http://www.parasitology.org/imagehtml/Fhepatica.htm>.
"Fasciola Hepatica." Zoo Lab. U. of Wisconsin. 19 May 2001 <http://bioweb.uwlax.edu/zootest/table%5Fof%5Fcontents/lab%2D04/fasciola/fasciola.htm>.
"Fasciola Hepatica: The Liver Fluke." Cambridge U. Schistosome Research Group. 11 May 2001 <http://www.path.cam.ac.uk/~tjs16/OtherFlukes/Fasciola.html>.
"Fascioliasis." Health Network. 19 May 2001 <http://www.healthnetwork.com.au/search-conditions-display.php3?name=FASCIOLIASIS>.
"Intestinal Parasites: Burdens and Trends." WHO Online. 11 May 2001 <http://www.who.int/ctd/intpara/burdens.htm>.
Katz, Michael, Dickson D. Desponnier, Robert W. Gevadz. Parasitic Disease. 2nd ed. New York: Springer-Verlag, 1989.
Malek, Emile A. Snail-Transmitted Parasitic Diseases. 2 vols. Boca Raton: CRC Press, 1980.
Markell, Edward K., David T. John, and Wojciech A. Krotski. Markell and Voge's Medical Parasitology. 8th ed. Philadelphia: W. B. Saunders Co., 1999.
"Parasites and Health: Fascioliasis." Center for Disease Control Online. 11 May 2001 <http://www.dpd.cdc.gov/dpdx/HTML/Fascioliasis.htm>.
Sun, Tsieh. Parasitic Disorders: Pathology, Diagnosis and Management. Baltimore: Williams and Wilkes, 1999.
Sun, Tsieh. Pathology and Clinical Features of Parasitic Disease. New York: Masson Pub. USA, 1982
Tolan, Robert. "Fascioliasis from Pediatrics/Parasitology." eMedicine. 19 May 2001 <."http://www.emedicine.com/ped/topic/760.htm>.
"Triclabendazole and Fascioliasis - A New Drug to Combat an Age-Old Disease." WHO Fact Sheet. n.191. 1998, 11 May 2001 <http://www.who.int/inf-fs/en/fact191.html>.